Literature DB >> 24797822

Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens.

Nandita Khera1, Amy Emmert2, Barry E Storer2, Brenda M Sandmaier2, Edwin P Alyea2, Stephanie J Lee2.   

Abstract

Reduced intensity conditioning (RIC) regimens have allowed older patients and those with comorbidities to receive hematopoietic cell transplantation (HCT). We analyzed medical costs from the beginning of conditioning to 100 days after HCT for 484 patients and up to 2 years for 311 patients who underwent a RIC HCT at two institutions from January 2008 to December 2010. Multiple linear regression was used to analyze the association between clinical variables, center effect, and costs. Patient and transplant characteristics were comparable between the sites, although differences were seen in pretransplant performance scores. Significant predictors for lower costs for the first 100 days included a diagnosis of lymphoma/myeloma and use of human leukocyte antigen-matched related donors. Grade II-IV acute graft-versus-host disease (GVHD) was associated with higher costs. The overall short-term costs between the two institutions were comparable when adjusted for clinical variables (p = .43). Late costs between 100 days and 2 years after HCT were available for one cohort (n = 311); median costs during this period were $39,000 and accounted for 39% of costs during the first 2 years. Late costs were not associated with any pretransplant variables, but were higher with extensive chronic GVHD and death. After adjustment for clinical characteristics, the overall costs of the RIC transplants were similar between the two institutions despite different management approaches (inpatient vs. outpatient conditioning) and accounting methodologies. Use of unrelated/alternative donors, transplant for diseases other than lymphoma or myeloma, and acute GVHD were predictors for higher early costs, and extensive chronic GVHD and death were associated with higher late costs. ©AlphaMed Press.

Entities:  

Keywords:  Allogeneic transplantation; Costs; Economics; Hematopoietic stem cell transplantation

Mesh:

Year:  2014        PMID: 24797822      PMCID: PMC4041670          DOI: 10.1634/theoncologist.2013-0406

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  23 in total

1.  Overcoming the age barrier in hematopoietic stem cell transplantation: progress, but still a long way to go.

Authors:  Shin Mineishi
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

2.  Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

Authors:  George B McDonald; John T Slattery; Michelle E Bouvier; Song Ren; Ami L Batchelder; Thomas F Kalhorn; H Gary Schoch; Claudio Anasetti; Ted Gooley
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

3.  Predicting costs of stem-cell transplantation.

Authors:  S J Lee; N Klar; J C Weeks; J H Antin
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting?

Authors:  J D Rizzo; G B Vogelsang; S Krumm; B Frink; V Mock; E B Bass
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation.

Authors:  B-M Svahn; M Remberger; O Alvin; H Karlsson; O Ringdén
Journal:  Bone Marrow Transplant       Date:  2011-08-29       Impact factor: 5.483

6.  The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.

Authors:  Karim E Abou-Nassar; Haesook T Kim; Jeff Blossom; Vincent T Ho; Robert J Soiffer; Corey S Cutler; Edwin P Alyea; John Koreth; Joseph H Antin; Philippe Armand
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-08       Impact factor: 5.742

7.  Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation.

Authors:  Tapani Ruutu; Britta Eriksson; Kari Remes; Eeva Juvonen; Liisa Volin; Mats Remberger; Terttu Parkkali; Hans Hägglund; Olle Ringdén
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

8.  Costs of second allogeneic hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Brenda M Sandmaier; Michael K Chapko; Stephanie J Lee
Journal:  Transplantation       Date:  2013-07-15       Impact factor: 4.939

9.  Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

Authors:  Amin M Alousi; Jennifer Le-Rademacher; Rima M Saliba; Frederick R Appelbaum; Andrew Artz; Jonathan Benjamin; Steven M Devine; Fangyu Kan; Mary J Laughlin; Hillard M Lazarus; Jane Liesveld; Miguel-Angel Perales; Richard T Maziarz; Mitchell Sabloff; Edmund K Waller; Mary Eapen; Richard E Champlin
Journal:  Blood       Date:  2013-01-29       Impact factor: 22.113

10.  Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database.

Authors:  N S Majhail; L W Mau; E M Denzen; T J Arneson
Journal:  Bone Marrow Transplant       Date:  2012-07-09       Impact factor: 5.483

View more
  18 in total

Review 1.  Childhood to adult transition and long-term follow-up after blood and marrow transplantation.

Authors:  M C Cupit; C Duncan; B N Savani; S K Hashmi
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

2.  Costs of hematopoietic stem cell transplantation in a developing country.

Authors:  Monica M Rivera-Franco; Eucario Leon-Rodriguez; Haydee L Castro-Saldaña
Journal:  Int J Hematol       Date:  2017-06-14       Impact factor: 2.490

Review 3.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

4.  Association of hematopoietic cell transplantation-specific comorbidity index with resource utilization after allogeneic transplantation.

Authors:  L Decook; Y-H Chang; J Slack; D Gastineau; J Leis; P Noel; J Palmer; L Sproat; M Sorror; N Khera
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

5.  Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients.

Authors:  Lynn El Haddad; Shashank S Ghantoji; Anne K Park; Marjorie V Batista; Jonathan Schelfhout; Jack Hachem; Yadira Lobo; Ying Jiang; Gabriela Rondon; Richard Champlin; Roy F Chemaly
Journal:  J Med Virol       Date:  2019-09-03       Impact factor: 2.327

Review 6.  The role of second transplants for leukemia.

Authors:  Daniel Weisdorf
Journal:  Best Pract Res Clin Haematol       Date:  2016-10-19       Impact factor: 3.020

7.  Cost structure and clinical outcome of a stem cell transplantation program in a developing country: the experience in northeast Mexico.

Authors:  José Carlos Jaime-Pérez; Alberto Carlos Heredia-Salazar; Olga G Cantú-Rodríguez; Homero Gutiérrez-Aguirre; César Daniel Villarreal-Villarreal; Consuelo Mancías-Guerra; José Luís Herrera-Garza; David Gómez-Almaguer
Journal:  Oncologist       Date:  2015-03-06

8.  Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.

Authors:  Fevzi F Yalniz; Mohammad H Murad; Stephanie J Lee; Steven Z Pavletic; Nandita Khera; Nilay D Shah; Shahrukh K Hashmi
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-14       Impact factor: 5.742

9.  Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.

Authors:  Scott F Huntington; Gottfried von Keudell; Amy J Davidoff; Cary P Gross; Sapna A Prasad
Journal:  J Clin Oncol       Date:  2018-10-04       Impact factor: 44.544

10.  Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors.

Authors:  Shernan G Holtan; Nandita Khera; John E Levine; Xiaoyu Chai; Barry Storer; Hien D Liu; Yoshihiro Inamoto; George L Chen; Sebastian Mayer; Mukta Arora; Jeanne Palmer; Mary E D Flowers; Corey S Cutler; Alexander Lukez; Sally Arai; Aleksandr Lazaryan; Laura F Newell; Christa Krupski; Madan H Jagasia; Iskra Pusic; William Wood; Anne S Renteria; Gregory Yanik; William J Hogan; Elizabeth Hexner; Francis Ayuk; Ernst Holler; Phandee Watanaboonyongcharoen; Yvonne A Efebera; James L M Ferrara; Angela Panoskaltsis-Mortari; Daniel Weisdorf; Stephanie J Lee; Joseph Pidala
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.